{"id":"W4317213523","doi":"10.1093/ndt/gfad009","title":"The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease","year":2023,"lang":"en","type":"article","venue":"Nephrology Dialysis Transplantation","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":237,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Center for Advancing Translational Sciences; Centers for Disease Control and Prevention; National Institutes of Health; National Heart, Lung, and Blood Institute; Vifor Pharma; Astellas Pharma; Novo Nordisk; Eli Lilly and Company; AstraZeneca; CSL Behring; MyoKardia; McMaster University; Gilead Sciences; FibroGen; Alnylam Pharmaceuticals; European Commission; Sanofi; American Society of Nephrology; GlaxoSmithKline; National Institute of Diabetes and Digestive and Kidney Diseases; Amgen","keywords":"Semaglutide; Medicine; Kidney disease; Diabetes mellitus; Type 2 diabetes; Urology; Internal medicine; Endocrinology; Liraglutide","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005240916,0.0001526657,0.0003382526,0.000180809,0.00008280306,0.00001841217,0.00008133047,0.00004232585,0.00001576856],"category_scores_gemma":[0.0001293286,0.00009123689,0.00002266753,0.0004371645,0.0001416896,0.0001167638,0.00002051402,0.00006620568,0.00000323377],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002273674,"about_ca_system_score_gemma":0.0002712689,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002535768,"about_ca_topic_score_gemma":0.0005942685,"domain_scores_codex":[0.9988523,0.0001646575,0.0002427142,0.000323173,0.0002067224,0.0002104566],"domain_scores_gemma":[0.998821,0.0005832404,0.00008354149,0.0003141793,0.00004746168,0.0001505459],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.08400442,0.0006852962,0.8850851,0.001109724,0.003192892,0.0001456965,0.001811768,0.003451972,0.001654643,0.0002398444,0.005689203,0.01292942],"study_design_scores_gemma":[0.0902218,0.003424495,0.8010402,0.0002616971,0.007386888,0.000003806444,0.0001253535,0.09468354,0.0002987215,0.0001506139,0.002093418,0.0003094917],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9903545,0.0002523306,0.001193176,0.00651724,0.00004560533,0.001442836,0.0001280851,0.00004414173,0.00002207887],"genre_scores_gemma":[0.9885827,0.0028465,0.001684247,0.001210426,0.00007104268,0.0002590501,0.00507197,0.00002405853,0.0002500523],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09123156,"threshold_uncertainty_score":0.3720532,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01992195976321406,"score_gpt":0.2595491731959684,"score_spread":0.2396272134327544,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}